BAM
GILD icon

Brave Asset Management’s Gilead Sciences GILD Stock Holding History

Brave Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,000
Closed -$284K – 153
2017
Q2 		$284K Buy
+4,000
New +$266K 0.15% 107

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brave Asset Management's GILD Position: Q3 2021 in Review

Brave Asset Management sold out of Gilead Sciences (GILD) in Q3 2021, closing a stake of 5,724 shares — an estimated $394K sold.

Brave Asset Management first reported a position in GILD in Q4 2013 and held it in 30 quarters. The position peaked at $2.64M in Q3 2016. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

  • Brave Asset Management reported no remaining Gilead Sciences position as of Q3 2021 after selling out during the quarter.
  • Brave Asset Management sold 5,724 Gilead Sciences shares in Q3 2021, an estimated $394K.
  • Brave Asset Management first reported a position in Gilead Sciences in Q4 2013 and held it in 30 quarters.
  • Brave Asset Management's Gilead Sciences position peaked at $2.64M in Q3 2016.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Brave Asset Management's 13F filing for Q3 2021, filed 2 Nov 2021.